These results provide a fundamental FDX1 expression profile to predict copper chelator sensitivity and suggest that FDX1 is a promising novel biomarker with an effective prognostic value for ccRCC. The gene discussed is FDX1; the disease is nonpapillary renal cell carcinoma.